Overview

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Rochester

Treatments:

Azacitidine
Decitabine
Everolimus
Ribavirin
Sirolimus